Welcome to our dedicated page for Satellos Bioscience SEC filings (Ticker: MSLE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Satellos Bioscience's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Satellos Bioscience's regulatory disclosures and financial reporting.
Satellos Bioscience Inc. has entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market equity offering program. Under this arrangement, Satellos may, from time to time, issue and sell up to $50,000,000 of its common shares through Leerink as sales agent, subject to board-authorized limits and available capacity under its shelf registration.
Sales will be made only in the United States as an “at the market offering” under Rule 415(a)(4), primarily through Nasdaq or other U.S. trading markets, at prevailing market prices. No offers or sales will occur in Canada or over Canadian exchanges. Leerink will use commercially reasonable efforts to place shares but is not obligated to buy them as principal without a separate agreement.
The ATM program is issued off Satellos’ previously filed short form base shelf prospectus and related Form F-10 registration statement, which provide for the potential offer and sale of up to $300,000,000 of securities overall. The company retains full discretion over when to deliver placement notices, the size and timing of sales, and may suspend or terminate offerings at any time.
Satellos Bioscience Inc. is a clinical-stage biotech focused on small‑molecule treatments for degenerative muscle diseases, led by SAT‑3247 for Duchenne muscular dystrophy (DMD). For the six months ended June 30, 2026, it reported a net loss of $21,486 (vs. $11,749 in 2025) as research and development and general and administrative expenses increased with the ramp-up of Phase 2 BASECAMP and TRAILHEAD trials and public-company costs.
R&D expenses rose to $16,945 for the six-month period, while G&A reached $5,263. The company has no revenue and an accumulated deficit of $103,456. Liquidity improved after a February 2026 equity offering raising $51,901 in net proceeds, bringing cash and short-term investments to $61,839 as of June 30, 2026; management believes this funds planned operations for the next 12 months.
Clinical and regulatory momentum continued: SAT‑3247 has Orphan Drug, Rare Pediatric Disease, and, as of June 29, 2026, Fast Track designation from the FDA for DMD. BASECAMP is enrolling 51 ambulatory boys with DMD globally, and TRAILHEAD is following adult DMD participants over 12 months, with interim data showing biomarker and imaging signals consistent with prior Phase 1 findings.
Satellos Bioscience Inc. filed an amended and restated short form base shelf prospectus and Form F-10 to register up to US$300,000,000 of common shares, preferred shares, warrants, units, subscription receipts and debt securities that may be offered over a 25‑month period. Specific terms, pricing, and structures will be set in future prospectus supplements and may include both fixed and non-fixed price distributions via underwriters, dealers, agents or direct sales. As of March 31, 2026, Satellos reported cash, cash equivalents and short-term investments of US$69.9 million and working capital of US$70.66 million, and intends to use any net proceeds primarily for R&D, advancing lead drug candidate SAT‑3247 through clinical trials, and general corporate purposes. Satellos is a clinical-stage company focused on degenerative muscle diseases; SAT‑3247 has FDA Fast Track designation for Duchenne and is being evaluated in ongoing clinical trials, with six‑month interim TRAILHEAD data in adults showing signals such as reduced muscle fat fraction and stable strength.
Satellos Bioscience reported six-month interim data from TRAILHEAD, an open-label Phase 2 study of SAT-3247 in four adults with Duchenne muscular dystrophy. MRI muscle fat fraction improved on average from 49.7% at baseline to 46.0% at month 6, a 3.7% absolute reduction. Mean total effort (TE99C) rose about 34%, from 16.1 joules/kg in the prior CL-101 study to 21.6 at month 6, while upper extremity strength measures, including handgrip, remained stable after a near-doubling seen in CL-101. Mean creatine kinase declined 38% from 2130 u/l to 1315 u/l. SAT-3247 was well tolerated with no serious treatment-emergent adverse events, no discontinuations, 100% compliance and about 186 days of mean exposure. Patient-reported fatigue (PedsQL-MFS) improved by 6.94 points, and Performance of the Upper Limb 2.0 scores were stable or slightly better. Satellos reiterates plans to complete BASECAMP pediatric enrollment and initiate U.S. TRAILHEAD sites in Q3 2026, with BASECAMP topline and TRAILHEAD 12‑month readouts expected in Q4 2026.
Satellos Bioscience Inc. has received FDA Fast Track designation for its oral small-molecule candidate SAT-3247 for Duchenne muscular dystrophy. SAT-3247 already holds Orphan Drug and Rare Pediatric Disease designations, underscoring regulatory support for this program. The drug is in Phase 2 BASECAMP and TRAILHEAD studies in pediatric and adult Duchenne patients, with additional data expected in the second half of 2026. SAT-3247 targets AAK1 to restore muscle repair signals in a dystrophin-independent manner, which may allow use across mutation types and potentially in other degenerative muscle diseases.
Satellos Bioscience Inc., a clinical-stage biotechnology company, reported that it will present new data from its SAT-3247 clinical development program at the 19th International Congress on Neuromuscular Diseases in Florence, Italy from July 7–11, 2026. The company will share six-month follow-up results from participants who completed its Phase 1b SAT-3247-CL-101 trial and entered the ongoing Phase 2 TRAILHEAD (LT-001) study, and will also give a Showcase Theatre presentation.
SAT-3247 is an investigational, orally administered small molecule designed to enhance muscle repair and regeneration in Duchenne muscular dystrophy and other degenerative muscle diseases by targeting AAK1. It is being evaluated in two Phase 2 trials, BASECAMP in pediatric patients and TRAILHEAD in adults, and is not yet approved by any health authority.
Satellos Bioscience Inc. reports the results of its Annual Meeting of Shareholders held on June 17, 2026. Shareholders present or represented by proxy accounted for 55.3% of the issued and outstanding common shares, providing a solid participation base for governance decisions.
All director nominees listed in the May 14, 2026 management information circular were elected, with most receiving over 99% of votes cast in their favor. Satellos shareholders also approved the re-appointment of PricewaterhouseCoopers LLP as the Company’s auditors.
The filing also reiterates that Satellos is a clinical-stage drug development company advancing SAT-3247 in two Phase II trials for degenerative muscle diseases, including Duchenne muscular dystrophy, and includes standard forward-looking statement disclosures outlining development and regulatory risks.
Satellos Bioscience Inc. reported the results of its annual shareholder meeting held virtually on June 17, 2026. Shareholders elected all nominated directors, with support levels generally very high.
Turnout was solid, with approximately 55.33% of issued and outstanding shares represented in person or by proxy. Most directors received about 99% of votes cast in favour. Stephanie Brown received 92.22% support, and Iris Loew-Friedrich received 83.76% support, while all other nominees were supported by at least 99.69% of votes cast.
Satellos Bioscience Inc. announced that its management team will present at two investor conferences in June. The company will speak at the Jefferies Global Healthcare Conference on June 4, 2026 at 11:05 a.m. in New York, and at the Oppenheimer CNS & Neuro-Muscular Summit on June 10, 2026 at 10:15 a.m. in Miami. Presentations will be available via live webcast on Satellos’ investor relations site, with replays afterward, and management will hold one-on-one meetings with investors. Satellos is a clinical-stage drug developer advancing SAT-3247, an orally administered small molecule targeting AAK1, in two Phase II trials for Duchenne muscular dystrophy, one in pediatric patients (BASECAMP) and one in adults (TRAILHEAD).
Satellos Bioscience Inc. is calling a virtual-only annual general meeting of shareholders on June 17, 2026 at 1:00 p.m. Toronto time to review 2025 financial statements, elect directors and appoint auditors. Only shareholders of record as of May 12, 2026 may vote.
The circular explains detailed proxy and voting procedures for registered and non-registered shareholders, including the need for control numbers and invite codes to vote online. Management recommends voting in favour of all resolutions, including the reappointment of PricewaterhouseCoopers LLP as auditor.
The filing also outlines 2025 compensation for key executives and directors, stock option and RSU awards, and the structure of Satellos’ Equity Incentive Plan. That plan can cover up to 3,124,679 shares, with 2,766,563 awards outstanding and a 2025 burn rate of 7.9% of outstanding shares.